ARCHIVES

Five-Year Course of Tamoxifen Remains Standard Treatment In HR+ Breast Cancer

This article is from The Cancer Letter archive.

Vol. 25 No. 7 | July 26, 2002

Download PDF Visit The Full Archive

Related Articles

M.D. Anderson Wins 11th SPORE Grant.

July 3, 2008

Reviewers Note Major Flaws In Design Of Burzynski’s Trials

September 25, 1998

In Brief: NIH Budget Cut Being Considered, Threatening NCI’s Plan For Reaching Year 2000 Goals

December 13, 1984

NCI Takes Action Against Investigators Who Gave Drug Without An IND; M.D. Anderson Contract Canceled

August 28, 1981

FDA, ASCO Meet to Review Drug Approval Endpoints

April 25, 2003

No Cancer Letter For Two Weeks

August 10, 1990